Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

Shares of direct-to-consumer telehealth platform Hims & Hers Health (NYSE: HIMS) have become a runaway freight train. The ...

Shares of Hims & Hers (NYSE: HIMS) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the ...

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $36.43, ...

In this video, I will talk about recent updates regarding Hims & Hers Health (HIMS-1.85%). Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock ...

BTIG analyst David Larsen raised the firm’s price target on Hims & Hers (HIMS) to $85 from $35 and keeps a Buy rating on the shares. The ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

Morgan Stanley analyst Craig Hettenbach downgraded Hims & Hers to Equal Weight from Overweight with a price target of $60, up from $42. The ...